ArticleTherapeutic advances in drug safety2025

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Tingting Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.